2010 Annual Meeting Program Book
The Journey to Optimal Treatment Strategies for
the OA Patient with Hypertension
Chairperson: Michael A. Weber, MD, Brooklyn, NY
Program Agenda:
6:00 AM Welcome and Introductions
Michael A. Weber, MD
6:10 AM NSAIDs, Blood Pressure and Cardiovascular Risk:
Understanding the Risks for Osteoarthritis Patients
Andrew Whelton, MD, Baltimore, MD
6:30 AM Nitric Oxide: The Journey from Basic Biology to
Therapeutic Potential
Leopoldo Raij, MD, Miami, FL
6:55 AM CINODs: A New Option in the Management of
Osteoarthritis Patients with Hypertension
Michael A. Weber, MD
7:20 AM Panel Discussion/Questions and Answers
All Faculty
Learning Objectives:
• Review the current available options for the
treatment of osteoarthritis (OA) and evaluate
their potential benefits and risks
• Discuss the relationship of background
antihypertensive therapy in NSAID-induced
blood pressure destabilization
• Summarize the outcomes associated with
endothelial dysfunction and decreased
bioavailability of nitric oxide
• Evaluate the data and potential utility of
Cyclooxygenase-Inhibiting Nitric Oxide Donating
(CINOD) drugs
Breakfast will be served at 5:45 AM in the
Trianon Ballroom.
mais nous avons aussi3 Non-Cardiac Drugs that Raise Blood Pressure
Chairs: Franz Messerli, MD, New York, NY and
Elijah Saunders, MD, Baltimore, MD
Original Communications
6:00 PM OR-9: Hyperuricemia, Cronotherapy with
Alopurinol and Hypertension
Carlos Calvo,1 Alvaro Hermida,1 José Enrique Lopez,1
Marta Pena,1 Luisa Romero,1 Gaila Calvo,1 Antonio
Coca.2 1Hypertension and Vascular Risk Unit.
Complejo Hospitalario Universitario de Santiago,
ES and 2Unit Hypertension, Hospital Clinico de
Barcelona, ES.
6:15 PM OR-10: The Nitric Oxide Donator Naproxcinod Has
Blood Pressure Effects Similar to Placebo in Patients
with Osteoarthritis
W. B. White†,1 T. Schnitzer,2 J. Dijian,3 H. Frayssinet,3
B. Duquesroix,3 M. A. Weber.4 1University of
Connecticut School of Medicine, Farmington, CT,
US; 2Northwestern University Feinberg School of
Medicine, Chicago, IL, US; 3Nicox, S.A., Sophia-
Antipolis, FR and 4SUNY Downstate College of
Medicine, Brooklyn, NY, US.6:30 PM OR-11: Different Effects of Aliskiren/
Hydrochlorotiazide and Atenolol/
Hydrochlorotiazide Combinations on Central
Pressure in Elderly Hypertensive Patients
Roberto Fogari, Amedeo Mugellini, Paola Preti,
Maurizio Destro, Luca Corradi, Giuseppe Derosa.
Department of Internal Medicine, University of Pavia,
Pavia, IT.
6:45 PM OR-12: Factors Influencing the Ambulatory Blood
Pressure Response to Low-Dose Aspirin in Subjects
with Untreated Mild Hypertension
Diana E. Ayala, Ramon C. Hermida, Maria J. Fontao,
Artemio Mojon, Jose R. Fernandez. University of Vigo,
ES.
7:00 PM Blood Pressure Increases from Non-cardiac
Therapies Including Arthritis Meds, Psychotropics,
Neurological Drugs, Angiogenesis Blockers
Ehud Grossman, MD, Tel Hashomer, Israel
mais encore!!Targeting Endothelial Dysfunction in Hypertensive
Cardiovascular Disease: Why, When, and How
Chairperson: Thomas D. Giles, MD, New Orleans, LA
Program Agenda:
6:00 AM Introduction: New Evidence for Targeting Critical
Mechanisms in Hypertensive Heart Disease
Thomas D. Giles, MD
6:25 AM Race-Specific Differences in Endothelial
Dysfunction: Relevance to Management of
Hypertension
R. Preston Mason, PhD, Boston, MA
6:50 AM Targeting Endothelial Dysfunction in the
Management of Cardiovascular Disease
Alan H. Gradman, MD, Pittsburgh, PA
7:15 AM Panel Discussion and Concluding Remarks
Thomas D. Giles, MD
Learning Objectives:
• Describe the role of nitric oxide in endothelial
dysfunction and in the pathogenesis of
hypertension, and hypertensive cardiovascular
disease, including LVH and heart failure
• Evaluate the relationship between oxidative stress
and endothelial function and its relevance to the
management of hypertensive patients
• Identify pre-clinical and clinical evidence
supporting the concept that there are race-based
differences in endothelial function which may
have clinical ramifications
• Analyze the pharmacologic differences among
β-blockers, including those with vasodilating
properties, and outline the evidence for the
clinical impact of these properties, especially on
tolerability and efficacy
Breakfast will be served at 5:45 AM in the
Trianon Ballroom.
Désolé encore (que des spécialistes qui ont publiés avec nicox)
7:30 PM – 9:00 PM • Trianon Ballroom
A Cross Examination of Contemporary Issues in
Hypertension: Today’s Controversy and Consensus
Chairperson: George L. Bakris, MD, Chicago, IL
Program Agenda:
7:30 PM Introduction and Opening Remarks
George L. Bakris, MD
7:35 PM Debate #1:
Setting Treatment Goals in Hypertension Care
Domenic A. Sica, MD, Richmond, VA
William B. White, MD, Farmington, CT
8:00 PM Summary Comments/Questions & Answers
Moderated by George L. Bakris, MD
8:05 PM Case Study Discussion: Combining Blood Pressure-
Lowering Agents and Emerging Treatment Options
William B. White, MD
Panel Discussion
All Faculty
8:20 PM Debate #2:
Using Biomarkers to Assess Risk in Hypertension
Patients
Domenic A. Sica, MD
William B. White, MD
8:45 PM Summary Comments/Questions & Answers
Moderated by George L. Bakris, MD
Learning Objectives:
• Optimize cardiovascular risk reduction by
establishing appropriate hypertension treatment
goals and providing blood pressure monitoring
that accurately gauges progress toward treatment
goals
• Improve assessment of individual cardiovascular
risk using biomarkers to guide the development
and adjustment of blood pressure–lowering
regimens
• Develop individualized blood pressure–lowering
regimens that optimally employ currently
available antihypertensive agents, either
individually or in combination
Dinner will be served at 7:30 PM in the
Les posters(connus)
PO-255: 2 Naproxcinod Produces Relaxation in Human
Mammary Arteries Showing Endothelial
Dysfunction
Daniela Miglietta,1 Alessandra Poggi,1 Barbara
Vergani,2 Guido Gelpi,3 Julio Padron,1 Manlio Bolla†.1
1NicOx Research, Bresso, IT; 2MIA Consortium,
PO-1: 3 The Cyclooxygenase Inhibiting Nitric Oxide Donator
(CINOD) Naproxcinod Induces Less Increases in
the 24-Hour Systolic Blood Pressure than Naproxen
and Ibuprofen in Patients with Osteoarthritis and
Hypertension
William B. White†,1 Thomas Schnitzer,2 Pascal
Longlade,3 Rosanna Fleming,3 Jacques Dijian.3
1University of Connecticut School of Medicine,
Farmington, CT, US; 2Northwestern University
Feinberg School of Medicine, Chicago, IL, US and
3Nicox, S.A., Sophia-Antipolis, FR.